Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marian Loffredo

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Cancer|March 1, 2024
Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trialTyler Walburn, Ming-Hui Chen, Marian Loffredo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2024
Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization AnalysisMutlay Sayan, Ming-Hui Chen, Marian Loffredo, et al.
JAMA Network Open|October 6, 2023
Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialMutlay Sayan, Jiaming Huang, Wanling Xie, et al.
Urology|August 30, 2003
Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancerMona V Sanghani, Delray Schultz, Clare M Tempany, et al.
Urology|January 22, 2019
Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation TherapyLuke R G Pike, Jing Wu, Ming-Hui Chen, et al.
The Lancet. Oncology|November 25, 2011
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trialsAnthony V D'Amico, Ming-Hui Chen, Mario de Castro, et al.
Cancer|April 6, 2021
Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortalityDanielle S Bitterman, Ming-Hui Chen, Jing Wu, et al.
Cancer|December 22, 2017
Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trialsKatelyn M Atkins, Ming-Hui Chen, Jing Wu, et al.
Journal of the National Cancer Institute|April 8, 2004
Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failureAnthony V D'Amico, Judd W Moul, Peter R Carroll, et al.
Urology|February 23, 2008
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682)Anthony V D'Amico, Susan Halabi, Robin Vollmer, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Cancer|March 1, 2024
Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trialTyler Walburn, Ming-Hui Chen, Marian Loffredo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2024
Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization AnalysisMutlay Sayan, Ming-Hui Chen, Marian Loffredo, et al.
JAMA Network Open|October 6, 2023
Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialMutlay Sayan, Jiaming Huang, Wanling Xie, et al.
Urology|August 30, 2003
Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancerMona V Sanghani, Delray Schultz, Clare M Tempany, et al.
Urology|January 22, 2019
Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation TherapyLuke R G Pike, Jing Wu, Ming-Hui Chen, et al.
The Lancet. Oncology|November 25, 2011
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trialsAnthony V D'Amico, Ming-Hui Chen, Mario de Castro, et al.
Cancer|April 6, 2021
Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortalityDanielle S Bitterman, Ming-Hui Chen, Jing Wu, et al.
Cancer|December 22, 2017
Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trialsKatelyn M Atkins, Ming-Hui Chen, Jing Wu, et al.
Journal of the National Cancer Institute|April 8, 2004
Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failureAnthony V D'Amico, Judd W Moul, Peter R Carroll, et al.
Urology|February 23, 2008
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682)Anthony V D'Amico, Susan Halabi, Robin Vollmer, et al.
Pageof 6